Skip to main content
NCBI home page
American Journal of Human Genetics logoLink to American Journal of Human Genetics
. 1993 Mar;52(3):616–626.

Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols.

R G Gregg 1, B S Wilfond 1, P M Farrell 1, A Laxova 1, D Hassemer 1, E H Mischler 1
PMCID: PMC1682167  PMID: 7680526

Abstract

We compare two protocols for newborn screening for cystic fibrosis (CF). The first uses the immunoreactive trypsinogen (IRT) assay with a cutoff of > or = 180 ng/ml and a sweat test to identify CF patients. The second uses the IRT assay with a 100 ng/ml cutoff in conjunction with direct analysis for the delta F508 CF transmembrane conductance regulator (CFTR) mutation in a two-tiered (i.e., IRT/DNA) protocol, followed by a sweat test. We screened 220,865 newborns from Wisconsin for CF, using the IRT protocol identifying 369 infants with an elevated IRT, of whom 46 were found to have CF. Another 7 CF patients were identified who had a false-negative IRT level. The CF incidence in the white population was 1 in 3,431 (carrier incidence of 1 in 30). The IRT protocol had a sensitivity of 87% and a positive predictive value of 12.5%. We subsequently used the IRT/DNA protocol to screen 21,258 infants. Of 518 infants with an IRT level > or = 100 ng/ml, 24 carried at least one copy of the delta F508 CFTR mutation, and 4 of these infants were found to have CF, yielding a positive predictive value for this protocol of 16.7%. Direct comparison of the positive predictive value of the two protocols is not valid, because of the different populations screened. However, had the IRT protocol been used on the IRT/DNA cohort, 50 infants, including the 4 with CF, would have received sweat tests, yielding a positive predictive value of 8%. Because of the small sample size, this positive predictive value is not significantly different from that obtained for the IRT/DNA test. However, from a practical point of view the IRT/DNA approach does decrease considerably the number of sweat tests that must be undertaken. The number of false positives for the IRT protocol (46 in 21,258) is increased significantly compared with that for the IRT/DNA approach (20 in 21,258; P < .001). The incidence of delta F508 carriers detected in cohorts with an elevated IRT level was increased compared with the incidence in the general population. The direct costs for the IRT/DNA approach (100 ng/ml) were $11,374 per CF patient detected, compared with $10,187 per CF patient detected for the IRT protocol. Therefore, we conclude that the IRT/DNA approach to CF newborn screening decreases the number of false-positive subjects contacted, without a significant increase in cost.

Full text

PDF
616

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adriaenssens K., Janssens H., van Soom H. Two tier screen for cystic fibrosis. Lancet. 1981 Apr 11;1(8224):833–833. doi: 10.1016/s0140-6736(81)92699-4. [DOI] [PubMed] [Google Scholar]
  2. Crossley J. R., Elliott R. B., Smith P. A. Dried-blood spot screening for cystic fibrosis in the newborn. Lancet. 1979 Mar 3;1(8114):472–474. doi: 10.1016/s0140-6736(79)90825-0. [DOI] [PubMed] [Google Scholar]
  3. Dankert-Roelse J. E., te Meerman G. J., Martijn A., ten Kate L. P., Knol K. Screening for cystic fibrosis. A comparative study. Acta Paediatr Scand. 1987 Mar;76(2):209–214. doi: 10.1111/j.1651-2227.1987.tb10449.x. [DOI] [PubMed] [Google Scholar]
  4. Fost N., Farrell P. M. A prospective randomized trial of early diagnosis and treatment of cystic fibrosis: a unique ethical dilemma. Clin Res. 1989 Sep;37(3):495–500. [PubMed] [Google Scholar]
  5. GIBSON L. E., COOKE R. E. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics. 1959 Mar;23(3):545–549. [PubMed] [Google Scholar]
  6. Hammond K. B., Abman S. H., Sokol R. J., Accurso F. J. Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations. N Engl J Med. 1991 Sep 12;325(11):769–774. doi: 10.1056/NEJM199109123251104. [DOI] [PubMed] [Google Scholar]
  7. Heeley A. F., Heeley M. E., King D. N., Kuzemko J. A., Walsh M. P. Screening for cystic fibrosis by died blood spot trypsin assay. Arch Dis Child. 1982 Jan;57(1):18–21. [PMC free article] [PubMed] [Google Scholar]
  8. Holtzman N. A. What drives neonatal screening programs? N Engl J Med. 1991 Sep 12;325(11):802–804. doi: 10.1056/NEJM199109123251109. [DOI] [PubMed] [Google Scholar]
  9. Jinks D. C., Minter M., Tarver D. A., Vanderford M., Hejtmancik J. F., McCabe E. R. Molecular genetic diagnosis of sickle cell disease using dried blood specimens on blotters used for newborn screening. Hum Genet. 1989 Mar;81(4):363–366. doi: 10.1007/BF00283692. [DOI] [PubMed] [Google Scholar]
  10. Kerem E., Corey M., Kerem B. S., Rommens J., Markiewicz D., Levison H., Tsui L. C., Durie P. The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508). N Engl J Med. 1990 Nov 29;323(22):1517–1522. doi: 10.1056/NEJM199011293232203. [DOI] [PubMed] [Google Scholar]
  11. Kulczycki L. L., Schauf V. Cystic fibrosis in blacks in Washington, DC: incidence and characteristics. Am J Dis Child. 1974 Jan;127(1):64–67. doi: 10.1001/archpedi.1974.02110200066009. [DOI] [PubMed] [Google Scholar]
  12. Laroche D., Travert G. Abnormal frequency of delta F508 mutation in neonatal transitory hypertrypsinaemia. Lancet. 1991 Jan 5;337(8732):55–55. doi: 10.1016/0140-6736(91)93377-l. [DOI] [PubMed] [Google Scholar]
  13. Lemna W. K., Feldman G. L., Kerem B., Fernbach S. D., Zevkovich E. P., O'Brien W. E., Riordan J. R., Collins F. S., Tsui L. C., Beaudet A. L. Mutation analysis for heterozygote detection and the prenatal diagnosis of cystic fibrosis. N Engl J Med. 1990 Feb 1;322(5):291–296. doi: 10.1056/NEJM199002013220503. [DOI] [PubMed] [Google Scholar]
  14. Lyon I. C., Crossley J. R., Smith P. A. Screening for cystic fibrosis. N Z Med J. 1983 Sep 14;96(739):673–675. [PubMed] [Google Scholar]
  15. Ramsey B. W., Farrell P. M., Pencharz P. Nutritional assessment and management in cystic fibrosis: a consensus report. The Consensus Committee. Am J Clin Nutr. 1992 Jan;55(1):108–116. doi: 10.1093/ajcn/55.1.108. [DOI] [PubMed] [Google Scholar]
  16. Ranieri E., Ryall R. G., Morris C. P., Nelson P. V., Carey W. F., Pollard A. C., Robertson E. F. Neonatal screening strategy for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis. BMJ. 1991 May 25;302(6787):1237–1240. doi: 10.1136/bmj.302.6787.1237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Roberts G., Stanfield M., Black A., Redmond A. Screening for cystic fibrosis: a four year regional experience. Arch Dis Child. 1988 Dec;63(12):1438–1443. doi: 10.1136/adc.63.12.1438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Rock M. J., Mischler E. H., Farrell P. M., Wei L. J., Bruns W. T., Hassemer D. J., Laessig R. H. Newborn screening for cystic fibrosis is complicated by age-related decline in immunoreactive trypsinogen levels. Pediatrics. 1990 Jun;85(6):1001–1007. [PubMed] [Google Scholar]
  19. Rommens J., Kerem B. S., Greer W., Chang P., Tsui L. C., Ray P. Rapid nonradioactive detection of the major cystic fibrosis mutation. Am J Hum Genet. 1990 Feb;46(2):395–396. [PMC free article] [PubMed] [Google Scholar]
  20. Ryley H. C., Deam S. M., Williams J., Alfaham M., Weller P. H., Goodchild M. C., Carter R. A., Bradley D., Dodge J. A. Neonatal screening for cystic fibrosis in Wales and the West Midlands: 1. Evaluation of immunoreactive trypsin test. J Clin Pathol. 1988 Jul;41(7):726–729. doi: 10.1136/jcp.41.7.726. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Tluczek A., Mischler E. H., Farrell P. M., Fost N., Peterson N. M., Carey P., Bruns W. T., McCarthy C. Parents' knowledge of neonatal screening and response to false-positive cystic fibrosis testing. J Dev Behav Pediatr. 1992 Jun;13(3):181–186. [PubMed] [Google Scholar]
  22. Wesley A. W., Smith P. A., Elliott R. B. Experience with neonatal screening for cystic fibrosis in New Zealand using measurement of immunoreactive trypsinogen. Aust Paediatr J. 1989 Jun;25(3):151–155. doi: 10.1111/j.1440-1754.1989.tb01440.x. [DOI] [PubMed] [Google Scholar]
  23. Wilcken B., Brown A. R., Urwin R., Brown D. A. Cystic fibrosis screening by dried blood spot trypsin assay: results in 75,000 newborn infants. J Pediatr. 1983 Mar;102(3):383–387. doi: 10.1016/s0022-3476(83)80653-2. [DOI] [PubMed] [Google Scholar]
  24. Wilcken B., Chalmers G. Reduced morbidity in patients with cystic fibrosis detected by neonatal screening. Lancet. 1985 Dec 14;2(8468):1319–1321. doi: 10.1016/s0140-6736(85)92623-6. [DOI] [PubMed] [Google Scholar]
  25. Wilfond Benjamin S., Fost Norman. The cystic fibrosis gene: medical and social implications for heterozygote detection. JAMA. 1990 May 23;263(10):2777–2783. [PubMed] [Google Scholar]

Articles from American Journal of Human Genetics are provided here courtesy of American Society of Human Genetics

RESOURCES